Phenoxybenzamine
| Clinical data | |
|---|---|
| Trade names | Dibenzyline | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682059 | 
| Pregnancy category | 
 | 
| Routes of administration | Oral | 
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 24 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.406 | 
| Chemical and physical data | |
| Formula | C18H22ClNO | 
| Molar mass | 303.83 g·mol−1 | 
| 3D model (JSmol) | |
| Chirality | Racemic mixture | 
| 
 | |
| 
 | |
| (verify) | |
Phenoxybenzamine (PBZ, marketed under the trade names Dibenzyline and Dibenyline) is a non-selective, irreversible alpha blocker.